MTDH and EphA7 are markers for metastasis and poor prognosis of gallbladder adenocarcinoma.

Abstract	Gallbladder cancer is an aggressive cancer with extremely poor prognosis. Over 90% of patients are diagnosed at an advanced, inoperable stage with metastasis and invasion to other organs. In this study, the expression of metadherin (MTDH) and erythropoietin-producing hepatoma-amplified sequence (Eph) receptor A7 (EphA7) in 96 benign and 108 malignant lesions of gallbladder was determined by immunohistochemistry, and their correlations with pathological features and prognosis were analyzed. Positive expression of EphA7 and MTDH was significantly higher in gallbladder adenocarcinoma than in benign lesions. In adenocarcinoma, the positive expression of EphA7 and MTDH was significantly associated with differentiation, tumor mass, lymphnode metastasis, invasion, and overall survival. Multivariate Cox regression analysis suggested that positive expression of EphA7 and MTDH was an independent poor-prognostic predictor in gallbladder adenocarcinoma. The elevated expression of EphA7 and/or MTDH is closely related to carcinogenesis, progression, clinical biological behaviors, and prognosis of gallbladder adenocarcinoma.
Authors	Dong-Cai Liu, Zhu-Lin Yang
Journal	Diagnostic cytopathology (Diagn Cytopathol) Vol. 41 Issue 3 Pg. 199-205 (Mar 2013) ISSN: 1097-0339 [Electronic] United States
PMID	21964981 (Publication Type: Journal Article)
Copyright	Copyright © 2011 Wiley Periodicals, Inc.
Chemical References	Biomarkers, Tumor Cell Adhesion Molecules MTDH protein, human Membrane Proteins RNA-Binding Proteins Receptor, EphA7
Topics	Adenocarcinoma (metabolism, mortality, secondary) Adult Aged Biomarkers, Tumor (metabolism) Cell Adhesion Molecules (metabolism) China (epidemiology) Female Gallbladder Neoplasms (metabolism, mortality, pathology) Humans Immunohistochemistry (methods) Lymph Nodes (pathology) Lymphatic Metastasis Male Membrane Proteins Middle Aged Neoplasm Invasiveness Prognosis RNA-Binding Proteins Receptor, EphA7 (metabolism) Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!